KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teladoc Health (TDOC) EBITDA (2016 - 2025)

Teladoc Health (TDOC) has disclosed EBITDA for 12 consecutive years, with -$25.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 49.16% to -$25.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$196.7 million through Dec 2025, up 80.39% year-over-year, with the annual reading at -$196.7 million for FY2025, 80.39% up from the prior year.
  • EBITDA hit -$25.3 million in Q4 2025 for Teladoc Health, up from -$48.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$16.1 million in Q4 2021 to a low of -$6.7 billion in Q1 2022.
  • Historically, EBITDA has averaged -$778.2 million across 5 years, with a median of -$75.5 million in 2023.
  • Biggest five-year swings in EBITDA: plummeted 23469.1% in 2022 and later surged 99.36% in 2023.
  • Year by year, EBITDA stood at -$16.1 million in 2021, then tumbled by 23469.1% to -$3.8 billion in 2022, then soared by 99.36% to -$24.4 million in 2023, then plummeted by 103.99% to -$49.7 million in 2024, then soared by 49.16% to -$25.3 million in 2025.
  • Business Quant data shows EBITDA for TDOC at -$25.3 million in Q4 2025, -$48.7 million in Q3 2025, and -$30.8 million in Q2 2025.